Akers Biosciences Inc (NASDAQ:AKER) said on Tuesday that its pharmaceutical partner MyMD Pharmaceuticals Inc has signed an agreement with a medical school to conduct a Phase 2 clinical trial of MYMD-1 to treat immune mediated depression in COVID-19 patients.
MyMD Pharmaceuticals Inc and the major medical school will launch a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19, a first of its kind expected therapy.
In a recent finding published in JAMA Network Open, about 52% of individuals who had COVID-19 had an associated moderate to severe Major Depressive Disorder.
Under a contract research agreement, the study is designed to analyze the pro-inflammatory cytokines associated with the cytokine storm, with the Phase 2 trial planned to begin in Q2. The COVID-19 depression trial is expected to be followed by studies at a major medical school on the therapeutic potential of MYMD-1 in patients with multiple sclerosis, including its effects on depression and disease progression.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates